In the third activity of this CME Outfitters BriefCase series, expert faculty utilize case-based learning to instruct learners on incorporating efficacy and safety data for biologics indicated for PsO and PsA in patients as part of treatment decision-making.
0.5
03/07/2024
Melodie S. Young, MSN, APRN, A/GNP-BC
Ms. Young is a Dermatology Nurse Practitioner at Mindful Dermatology and Modern Research Associates.
Melodie S. Young, MSN, APRN, A/GNP-BC
Melodie Young has more than 30 years in dermatology as a nurse practitioner and has focused her career on immune-mediated skin disease. She has been the Principal Investigator or Sub-Investigator in more than 80 clinical trials and has more than 40 scholarly publications. She is the former Director of the Baylor Psoriasis Center, National Psoriasis Tissue Bank, and a former member of the Medical Advisory Board of the National Psoriasis Foundation. Young is a founding member of the International Psoriasis Council.
In this second installment of a two-part Journal Club series, An Expanded View of Alzheimer’s Disease Neuropathology: Translation to the Early Identification of Disease, expert faculty will evaluate the latest data from ATT clinical trials and discuss strategies for identifying appropriate patients based on both pathological and clinical characteristics to ensure timely and optimal management of patients with early symptomatic AD.
In this first installment of a two-part Journal Club series, An Expanded View of Alzheimer’s Disease Neuropathology: Translation to the Early Identification of Disease, expert faculty will present the latest information on the neuropathological changes associated with AD, their relevance to the cognitive and functional decline of early AD, as well as the role of phosphorylated tau biomarkers as early indicators of both amyloid and tau accumulation.
Recent data has led to a debate of the most effective maintenance strategy for advanced OC. Emerging data utilizing novel approaches to maintenance both further complicates the debate and sheds new light on novel effective strategies for maintenance therapy for advanced OC, leaving clinicians struggling to adopt appropriate strategies. In order to ensure that clinical decisions align with the latest emerging data regarding maintenance therapy in OC, Drs. Richard Penson and Kathleen Moore will educate clinicians on the role of biomarkers in OC, incorporation of genetic testing, and interpretation of results as part of clinical practice.
0.5
02/28/2024
Kathleen N. Moore, MD
Kathleen N. Moore, MD
Richard T. Penson
Richard T. Penson, MD, MRCP, is a Medical Oncologist at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School. A key opinion leader, Dr. Penson was a longstanding member of the Gynecologic Oncology Group Ovarian and Quality of Life Committees and now serves on the Foundation’s Investigator Council.
Richard T. Penson
(Moderator)
Richard T. Penson, MD, MRCP, is a Medical Oncologist at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School. A key opinion leader, Dr. Penson was a longstanding member of the Gynecologic Oncology Group Ovarian and Quality of Life Committees and now serves on the Foundation’s Investigator Council. He is the national Principal Investigator (PI) of the olaparib registration trial (SOLO-2) and the international PI of SOLO3, and the OVAL trial. He has taught on Harvard’s Practice of Medicine Course, the Bigelow General Medical Service at Massachusetts General Hospital, and is one of the Chairs of the Institutional Review Board of Dana-Farber Harvard Cancer Center.
This CMEO digital monograph serves to highlight the presentations of a 2-day educational activity, moderated by Timothy Garvey, MD, which focused on co-occurrence of obesity with elevated A1C and other cardiometabolic risk factors, applications of incretin therapy, and intensification strategies and therapies in the management of T2D.
In the first activity of this CME Outfitters BriefCase series, expert faculty utilize case-based learning to guide learners through evaluating the impact of PsO and PsA on individual needs and concerns.
0.5
02/28/2024
Terry Faleye, MPAS, PA-C
Terry Faleye, MPAS, PA-C
Join our newsletter
Stay up to date on new CME Outfitters activities, breaking news, and important developments in medical education.